封面
市场调查报告书
商品编码
1084776

DNA修復药的世界市场规模、占有率、展望、机会分析 (2022年~2028年):药物 (Niraparib、Olaparib、Rucaparib、Talazoparib)、用途、流通管道、各地区

DNA Repair Drugs Market, by Drug (Niraparib, Olaparib, Rucaparib, Talazoparib, and Others), by Application by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 206 Pages | 商品交期: 2-3个工作天内

价格
简介目录

癌症的发生率增加,进入经营者的M&A,产品的销售增加等要素促进全球DNA修復药市场成长。还有为了强化产品系列的主要企业的无机策略也预期促进该市场的成长。

本报告提供全球DNA修復药的市场调查,市场定义和概要,市场成长的各种影响因素分析,法律制度,市场规模的变化、预测,各种区分、各地区/主要国家的明细,竞争环境,主要企业简介等彙整资讯。

目录

第1章 调查目的、前提条件

第2章 市场概要

第3章 市场动态、法律规章、趋势分析

  • 市场动态
    • 促进因素
    • 阻碍因素
    • 市场机会
  • 影响分析
  • 开发平台分析
  • 法规情境
  • 价格分析
  • PEST分析
  • 流行病学

第4章 全球DNA修復药市场:各药物类型

  • Niraparib(Zejula)
  • Olaparib(Lynparza)
  • Rucaparib(Rubraca)
  • Talazoparib(Talzenna)

第5章 全球DNA修復药市场:各用途

  • 卵巢癌
  • 乳癌

第6章 全球DNA修復药市场:各流通管道

  • 医院药局
  • 零售药局
  • 线上药局

第7章 全球DNA修復药市场:各地区

  • 北美
  • 南美
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第8章 竞争情形

  • 企业简介
    • AstraZeneca Plc.
    • Johnson &Johnson
    • GlaxoSmithKline plc.
    • Pfizer, Inc.
    • Clovis Oncology Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb
    • Merck KGaA
    • Genentech, Inc.
    • Artios Pharma
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • Karyopharm Therapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

第9章 Section

简介目录
Product Code: CMI2617

DNA repair drugs such as Niraparib (Zejula), Olaparib (Lynparza), Rucaparib (Rubraca), and Talazoparib (Talzenna) are used for treating ovarian and breast cancer. These drugs fall under the category of Poly ADP-ribose Polymerase (PARP) inhibitors used as monotherapy in combination with other drugs for treatment of cancer.

Market Dynamics

Increasing incidences of cancer, increasing collaboration and acquisition with product launch by market players are major factors driving global DNA repair drugs market growth. In May 2019, AstraZeneca and Merck received the Health Canada approval for Lynparza as monotherapy maintenance treatment for patients with advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer.

Furthermore, inorganic strategies adopted by key players to enhance their product portfolio is expected to drive the market growth. In May 2019, Clovis Oncology, Inc., in collaboration with Bristol-Myers Squibb Company and Foundation Medicine Inc., initiated Phase II trials to evaluate rucaparib in combination with nivolumab in patients with high-grade serous carcinoma (HGSC) or endometrioid ovarian cancer.

Key features of the study:

  • This report provides in-depth analysis of DNA repair drugs market and provides market size (US$ million) and compound annual growth rate (CAGR %) over the forecast period (2022-2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global DNA repair drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global DNA repair drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global DNA repair drugs market

Detailed Segmentation:

  • Global DNA Repair Drugs Market, By Drug Type:
    • Niraparib (Zejula)
    • Olaparib (Lynparza)
    • Rucaparib (Rubraca)
    • Talazoparib (Talzenna)
  • Global DNA Repair Drugs Market, By Application:
    • Ovarian Cancer
    • Breast Cancer
  • Global DNA Repair Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global DNA Repair Drugs Market, By Region:
    • North America
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type:
      • Niraparib (Zejula)
      • Olaparib (Lynparza)
      • Rucaparib (Rubraca)
      • Talazoparib (Talzenna)
      • By Application:
      • Ovarian Cancer
      • Breast Cancer
      • By Distribution Channel:
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • AstraZeneca Plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Johnson & Johnson
    • GlaxoSmithKline plc.
    • Pfizer, Inc.
    • Clovis Oncology Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb
    • Merck KGaA
    • Genentech, Inc.
    • Artios Pharma
    • Repare Therapeutics Inc.
    • Sierra Oncology, Inc.
    • Karyopharm Therapeutics Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Jiangsu Hengrui Medicine Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • Regulatory Scenario
  • Pricing Analysis
  • PEST Analysis
  • Epidemiology

4. Global DNA Repair Drugs Market, By Drug Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Niraparib (Zejula)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Olaparib (Lynparza)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Rucaparib (Rubraca)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Talazoparib (Talzenna)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

5. Global DNA Repair Drugs Market, By Application, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global DNA Repair Drugs Market , By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global DNA Repair Drugs Market , By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Company Profiles
    • AstraZeneca Plc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Johnson & Johnson
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Clovis Oncology Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AbbVie Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol Myers Squibb
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck KGaA
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Genentech, Inc.
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Market Strategies
    • Artios Pharma
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Market Strategies
    • Repare Therapeutics Inc.
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Market Strategies
    • Sierra Oncology, Inc.
    • Company Overview
    • Product Type Portfolio
    • Key Highlights
    • Market Strategies
    • Karyopharm Therapeutics Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ono Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact